EPATEPAT was designed to study the effects of estrogen replacement therapy (ERT) on the progression of early atherosclerosis in healthy postmenopausal women without preexisting cardiovascular disease (CVD).
In this trial A total of 222 healthy postmenopausal women 46 to 80 years old without CVD symptoms were randomized to receive either micronized 17B-estradiol (Estrace) 1mg/day, or a matching placebo tablet daily. Ultrasonography were used to measure the rate of change in the thickness of the carotid artery. Blood samples were used for measuring lipid and non-lipid mediators of ERT.

Funding Source

This study was supported by the National Institute on Aging and Hoffmann-La Roche, Inc.

Registered at clinicaltrials.gov under NCT00115024